

SYLUS PHARMACEUTICALS LTD

**Company Registration Number:
04389197 (England and Wales)**

Unaudited micro entity accounts for the year ended 31 March 2023

Period of accounts

Start date: 01 April 2022

End date: 31 March 2023

SYLUS PHARMACEUTICALS LTD

Contents of the Financial Statements

for the Period Ended 31 March 2023

Company Information - 3

Profit and Loss Account - 4

Balance sheet - 5

Footnotes to the Balance Sheet - 7

SYLUS PHARMACEUTICALS LTD

Company Information

for the Period Ended 31 March 2023

Registered office:

2a Dunmore Court
Wootton Road
Abingdon
England
OX13 6BH

Company Registration Number:

04389197 (England and Wales)

SYLUS PHARMACEUTICALS LTD

Profit and Loss Account

for the Period Ended 31 March 2023

	<i>2023</i> <i>£</i>	<i>2022</i> <i>£</i>
Turnover	-	81,060
Cost of Materials	-	(36)
Staff Costs	(67,500)	(89,804)
Depreciation and Writeoffs	(2,253)	(2,040)
Other charges	(16,147)	(3,695)
Profit or (Loss) for Period	(85,900)	(14,515)

SYLUS PHARMACEUTICALS LTD

Balance sheet

As at 31 March 2023

	<i>2023</i>	<i>2022</i>
	£	£
Fixed Assets:	3,537	5,790
Current assets:	201,869	281,110
Creditors: amounts falling due within one year:	(2,550)	(2,600)
Net current assets (liabilities):	199,319	278,510
Total assets less current liabilities:	202,856	284,300
Creditors: amounts falling due after more than one year:	(63,862)	(59,407)
Total net assets (liabilities):	138,994	224,893
Capital and reserves:	138,994	224,893

SYLUS PHARMACEUTICALS LTD

Balance sheet continued

For the year ending 31 March 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions of the small companies regime applicable to micro-entities.

This report was approved by the board of directors on 30 December 2023

And Signed On Behalf Of The Board By:

Name: Prof Thomas Rademacher

Status: Director

The notes form part of these financial statements

SYLUS PHARMACEUTICALS LTD

Footnotes to the Financial Statements

for the Period Ended 31 March 2023

1. Employee Information

Average number of employees: 1

SYLUS PHARMACEUTICALS LTD

Footnotes to the Financial Statements

for the Period Ended 31 March 2023

2. Off balance sheet disclosure

No

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.